Thursday 30 March 2006

Afternoon

14:00

Registration and hanging up of posters

15:30

Welcome (Hendrik Fuchs, Marco Colombatti)

15:40

Opening Talk:   Targeted Therapy — past, present, and future

16:00

Luzie Fabisch Memorial Lecture
Robert Kreitman
Therapy of chemoresistant hairy cell leukemia patients with recombinant immunotoxin BL22

16:45

Juergen Hess
Heterologous virus-like-particles: Recombinant nanosystems as versatile antigen delivery devices for cancer therapy

17:00

Coffee break

17:25

Edwin Bremer
Tumor cell-restricted apoptosis induction; therapeutic targeting of the messengers of death

18:00

Johannes Müthing
Tumor-associated CD75s-gangliosides and CD75s-bearing glycoproteins with Neu5Acα2-6Galβ1-4GlcNAc-residues are receptors for the anticancer drug rViscumin

18:07

Yvonne Andersson
Synergistic anticancer effects in vitro and in vivo of Pseudomonas exotoxin-containing immunotoxins and a non-cytostatic drug in clinical use.

18:15

Cristina Potrich
A tumor protease-activated pore forming toxin as a specific anticancer tool

18:22

Sajid Hussain
Ep-CAM-directed liposomal drug delivery systems for targeted cancer therapy

18:30

Horst Dürkop
CD30 as an immunotherapeutic target structure

19:05

David Flavell
Strategies to improve the efficacy of immunotoxin therapies

19:40

Coffee, snack and visit of posters

after it

Free time to explore Berlin by night

08:30

Arthur E. Frankel
Recombinant diphtheria and anthrax toxins for therapy of chemoresistant malignancies

09:10

Susanna Rybak
RNase-based Therapeutics: Update

09:45

Fiorenzo Stirpe
Ribosome-inactivating proteins as components of immunotoxins: advances, pros and cons

10:20

Coffee break

10:40

Giuseppe D'Alessio
Human anti-tumor immunoagents

11:15

Georg H. Fey
Targeting CD19 and CD33 by antibody-derived molecules for the treatment of leukemias and lymphomas

11:50

Hauke Lilie
Design of immunotoxins using a novel strategy to couple antibody fragment and toxin

12:25

Roberta Traini
Production of Ribosome-Inactivating Proteins and Immunotoxins in a yeast Pichia pastoris Expression System

12:32

Rainer Haag
Dendritic polymers for DNA and drug-delivery

12:40

Anke Schmidt
Discovery of Tumor Selective Peptides for Targeted Therapy of Medullary Thyroid Carcinoma

12:47

Nikola Holtkamp
PDGFRA and KIT dysregulation and mutation in malignant peripheral nerve sheath tumors (MPNST)

12:55

Edwin Bremer
Simultaneous activation of CD20- and Fas-apoptotic signaling; a novel therapeutic approach for B-cell malignancies

13:02

Gérard Déléris
Design, Synthesis and Evaluation of Novel Anticancer Agents or Nanodevices towards Inhibition and/or Imaging of Tumour Neoangiogenesis

13:10

lunch & posters

Friday 31 March 2006

Afternoon

14:30

Peter Borchmann
Targeted therapy with monoclonal antibody-conjugates for patients with Hodgkin's lymphoma

15:05

Deborah Castelletti / Marco Colombatti
T-cell and B-cell epitopes triggering a human immune response against ricin A-chain

15:40

Andreas Menrad
Therapeutic efficacy of the targeted immunocytokine L19-IL2 in orthotopic animal models for pancreatic- and hepatocellular carcinoma

15:55

Coffee break

16:20

Øystein Fodstad
Basic and translational research on immunotoxins and immunotoxin / drug combinations

16:55

Walter Hall
Anti-Angiogenic Targeted Toxins Against Malignant Gliomas

17:30

Regeneration period

18:30

Bus transfer to the Spree

19:00

Boat tour including dinner

23:00

Bus transfer to the hotel

Saturday 01 April 2006

Morning

09:00

Arjan A. van de Loosdrecht
Leukemia-derived dendritic cell therapy in acute myeloid leukemia

09:35

Richard Begent
Engineered Antibodies and Clinical Applications

10:10

Christopher Bachran / Hendrik Fuchs
A combination of saponin and chimeric adaptertoxins enhances the tumor therapeutic potential

10:45

Yong-Jiang Cao
Identification of tumor endothelial antigens by means of tissue panning using an antibody phage display library

11:00

Coffee break

11:25

Stefan Barth
Targeting activated macrophages

12:10

Raquel Muñoz
CD105 as target for anti-tumor immunotoxins

12:45

Concluding remarks (Hendrik Fuchs, Marco Colombatti)

13:00

End